摘要
目的探讨金属硫蛋白(Metallothionein,MT)在前列腺癌组织中的表达及临床意义。方法应用免疫组织化学方法观察不同分级的66例前列腺癌、20例前列腺增生组织MT的表达情况,分析MT与临床病理因素及预后之间的关系。结果20例前列腺增生组织MT的表达率为100%(20/20),66例前列腺癌组织中MT的表达率为59.1%(39/66),两者比较差异有统计学意义(P<0.05)。MT的表达随着前列腺癌组织学分级、临床分期的增加而增加(P<0.05);与患者血清PSA水平、年龄无相关性(P>0.05);MT阳性表达组与阴性表达组之间的生存率差异有统计学意义(P<0.05)。结论MT的表达与前列腺癌发生、发展及预后有一定的关系。
Objective To investigate the expression of metallothionein （MT） in prostatic carcinoma and its clinical significance. Methods The expressions of MT in 66 cases of different-grade prostatic carcinoma and in 20 cases of benign prostatic hyperplasia were detected by immunohistochemical technique, and the relationship between MT and clinicopathological features and their prognosis were analysed. Results The positive rate of MT expression in the 20 cases of benign prostatic hyperplasia was 100% （20/ 20）, while it was 59.1% （39/66） in the cases of prostatic carcinoma. The difference was significant （ P 〈 0.05 ）. With the increase in Gleason scoring and clinical stage, the expression of MT was increased in the cases of prostatic carcinoma （ P 〈 0.05 ） and there was no relationship between MT expression and serum prostate specific antigen （PSA） level or age （ P 〉 0.05 ）. The survival rate was significantly different between MT-positive and MT-negtive groups （P 〈0.05）. Conclusion The expression of MT is related to the development and the prognosis of prostatic carcinoma.
出处
《临床军医杂志》
CAS
2008年第6期853-855,共3页
Clinical Journal of Medical Officers
